On March 27, 2017 NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, reported the upcoming presentation of recent research in precision oncology and predictive biomarkers using the nCounter Analysis System (Press release, NanoString Technologies, MAR 27, 2017, View Source [SID1234518283]). More than 45 NanoString-related abstracts will be presented at the Annual Meeting of the American Association of Cancer Research (AACR) (Free AACR Whitepaper), which is being held April 1-5, 2017, in Washington, DC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are proud to see our products and technologies being used so broadly to advance the understanding of cancer. We salute these researchers and the groundbreaking contributions to cancer research that are being presented at the 2017 Annual Meeting of the AACR (Free AACR Whitepaper)," said Brad Gray, president and chief executive officer of NanoString Technologies. "Our nCounter technology has become an essential tool for biomarker research, and we continue to expand the capabilities and content to drive adoption in other areas of research such as autoimmune syndromes, infectious disease and neurology."

The 2017 AACR (Free AACR Whitepaper) abstracts describe research applications that underscore the diverse capabilities and robust performance of the nCounter platform. These studies cover a wide range of cancers, tissue types (FFPE, peripheral blood and urine), and treatment modalities. There are at least 33 abstracts authored by academic researchers and 13 by biopharma researchers. These abstracts span translational research from biomarker validation and disease characterization, to drug resistance and autoimmune toxicities of checkpoint inhibitors.

NanoString will be exhibiting at AACR (Free AACR Whitepaper) (booth# 3115) and hosting a workshop entitled "Powering Precision Oncology Research with 3D Biology Technology: High Plex Multi-Analyte Profiling on FFPE with Spatial Resolution" at 10:00am ET on Monday April 3.

Abstract # Title Hyperlink
471/12 HER2 regulates PARP-1 expression by suppressing the let-7a microRNA in HER2+ breast cancer View Source!/4292/presentation/2057
414/14 Identifying selective vulnerabilities in colorectal cancer molecular subtypes using in vivo functional genomic screens View Source!/4292/presentation/6665
811/17 Histological heterogeneity contributes to sunitinib resistance in clear cell renal cell carcinoma View Source!/4292/presentation/1784
588/22 Advanced molecular characterization of severe autoimmune toxicities associated with checkpoint inhibitor therapies View Source!/4292/presentation/6096
491/5 Elucidating de novo PATRR-mediated t(3;8) balanced translocation and clear cell renal cell carcinoma View Source!/4292/presentation/1159
829/7 MicroRNA regulation of radiation sensitivity in colorectal cancer View Source!/4292/presentation/2397
1682/1 Correlation of immune co-stimulatory molecule OX40 and outcome in trastuzumab treated HER2-positive breast cancer patients in the NCCTG-N9831. View Source!/4292/presentation/5987
1750/10 Analysis of non-metastatic HCC patient tumors revealed the significance of cell cycle regulation and tumor immunity in association with overall survival and identified clinically relevant druggable targets View Source!/4292/presentation/2931
1469/11 Integrated analysis of microRNA, mRNA, and protein expression utilizing MultiOmyx and NanoString from formalin-fixed paraffin-embedded, lung, head and neck, breast, and melanoma tumors View Source!/4292/presentation/2080
1785/15 Technical validation of novel 325 RNA predictive biomarkers using gene expression data generated by Nanostring n-counter and Affymetrix microarray View Source!/4292/presentation/1589
1904/5 Novel 5-fluorouracil-thymoquinone hybrid kills colon cancer stem cells View Source!/4292/presentation/5919
2088/15 The activity of the FGFR selective inhibitor Debio 1347 is correlated with high mRNA expression View Source!/4292/presentation/3926
2841/14 Investigating drivers of disease progression in invasive lobular carcinoma View Source!/4292/presentation/3513
2441/28 NanoString 3D Biology technology: simultaneous digital counting of DNA, RNA and protein View Source!/4292/presentation/6870
2251/5 Tumor tissue gene expression in association with survival of triple-negative breast cancer View Source!/4292/presentation/2562
2422/9 Simultaneous detection of activating somatic DNA mutations and expressed fusion transcripts from lung tumor FFPE samples View Source!/4292/presentation/6827
3814/10 A pan cancer analysis of the tumor inflammation signature View Source!/4292/presentation/1652
3612/11 Combination FGFR4 and ER-targeted therapy for invasive lobular carcinoma View Source!/4292/presentation/2276
3431/11 The oncogenic role of miR-150-5p in triple-negative breast cancer View Source!/4292/presentation/2127
3706/19 Validation of human and mouse myeloid panels on the NanoString nCounter Platform View Source!/4292/presentation/3240
3738/23 Use of tumor mRNA expression for patient selection in a phase I study of the pan-fibroblast growth factor receptor inhibitor BAY 1163877 View Source!/4292/presentation/3003
3955/22 Spatially resolved, multiplexed digital characterization of protein and mRNA distribution and abundance in formalin-fixed, paraffin-embedded (FFPE) tissue sections based on NanoString’s Digital Spatial Profiling (DSP) technology: applications to immuno-oncology (IO) and tumor heterogeneity View Source!/4292/presentation/3416
3652/25 Combinational activity of LAG3 and PD-1 targeted therapies is significantly enhanced by the addition of phosphatidylserine targeting antibodies and establishes an anti-tumor memory response in murine triple negative breast cancer View Source!/4292/presentation/6260
3983/26 A cross comparison of technologies for the detection of immune system related gene expression signatures in clinical FFPE samples of metastatic prostate cancer patients View Source!/4292/presentation/9068
3684/27 Inhibition of STAT3 by antisense oligonucleotide treatment decreases the immune suppressive tumor microenvironment in syngeneic and GEM tumor models View Source!/4292/presentation/6345
3423/3 Elucidation of the role of miR-575 on tumorigenesis in glioblastoma View Source!/4292/presentation/2119
3810/6 Validation of novel high-plex protein spatial profiling quantitation based on NanoString’s Digital Spatial Profiling (DSP) technology with quantitative fluorescence (QIF) View Source!/4292/presentation/1648
3377/8 Simultaneous analysis of the mutational landscape and RNA and protein expression profile of HER2-positive breast cancer using 3D Biology View Source!/4292/presentation/6631
NG04 Mechanisms of resistance to anti-PD-1 immunotherapy through interferon pathway mutations View Source!/4292/presentation/11061
4649/10 Development of an ethnicity informed gene expression panel with potential to improve prostate cancer diagnosis View Source!/4292/presentation/1628
4334/13 Interleukin-6 is a key player in stroma-induced resistance to chemotherapy for gastric carcinomas View Source!/4292/presentation/5224
4387/19 The clonal composition of colorectal cancer cell lines is defined by the maintenance of specific genomic imbalances, not by ongoing chromosomal instability View Source!/4292/presentation/6569
4197/20 Interaction of B lymphoma cells with the microenvironment affects ibrutinib sensitivity View Source!/4292/presentation/3904
4442/20 micoRNA in FA defective tumor View Source!/4292/presentation/2156
4262/28 Inflammatory gene expression differences among prostate cancer patients exposed to the World Trade Center aftermath View Source!/4292/presentation/4794
4971 IACS-010759, a novel inhibitor of complex I in Phase I clinical development to target OXPHOS dependent tumors View Source!/4292/presentation/3226
5000 A stromal liver gene signature predictive of HCC risk across all liver disease etiologies View Source!/4292/presentation/7455
5095/11 Development of a pharmacodynamic biomarker assay for AZD4785, an antisense oligonucleotide targeting KRAS View Source!/4292/presentation/2614
5448/13 An exosomal biomarker for prostate cancer View Source!/4292/presentation/2172
5645/17 Associations between biomarkers and outcome in a patient cohort with invasive lobular carcinoma View Source!/4292/presentation/993
5563/21 3D Biology view of cancer: Simultaneous detection of somatic DNA mutations and expression profiling of genes and signaling proteins from melanoma tumor FFPE samples View Source!/4292/presentation/1756
5726/20 A novel tumor-promoting role for miR-4516 in glioblastoma View Source!/4292/presentation/1479
5757/21 Study of human mammary tumor virus (HMTV) in human breast cancer by NanoString nCounter and FISH analysis View Source!/4292/presentation/2332
5652/6 Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma View Source!/4292/presentation/6014
5350/6 A comprehensive and integrated approach to genomic and proteomic analysis of FFPE NSCLC tumor specimens View Source!/4292/presentation/6724
5092/8 ZVex lentiviral vector strongly activates pro-inflammatory, antigen processing, and antiviral defense response pathways in monocyte-derived dendritic cells